|Day Low/High||0.58 / 0.77|
|52 Wk Low/High||0.46 / 3.47|
WaferGen (WGBS) is expected to report its 2016 second quarter results after Tuesday's closing bell.
Agreement Expands Access to WaferGen's Single-Cell and Clinical Research Products in the Asia-Pacific Region
Transaction scheduled to close following completion of the 2016 fiscal year
ICELL8™ Single-Cell System to Enable Innovative Stem Cell and Regenerative Medicine Research
Results From Genentech, Karolinska Institutet, National Jewish Health, and MD Anderson Cancer Center Highlight ICELL8™ Single-Cell System Performance
Researchers From Genentech, Karolinska Institutet and National Jewish Health to Present Results Using WaferGen's ICELL8™ Single-Cell System
Supply Agreement Enables Identification of Rare Blood Donors Using WaferGen's Proprietary SmartChip™ Technology
Agreement Expands WaferGen's European Customer Demonstration Laboratory Capabilities to include the ICELL8 Single-Cell System
System Now Fully Functional in Customer's Lab
These stocks trading for less than $10 a share are within range of breaking out and trading higher from current levels.
Supply Agreement Enables Automation of NGS Library Preparation for Preimplantation Genetic Screening Technology Used in IVF
Proceeds to be Used Primarily for Research and Development Initiatives and ICELL8(TM) Single-Cell System Commercialization Activities
WaferGen Bio-systems (WGBS) shares are lower after pricing the 3.92 million shares of common stock in its public offering.
Trade-Ideas LLC identified Wafergen Bio-systems (WGBS) as a weak on high relative volume candidate
WaferGen Bio-systems (WGBS) shares are higher after the company announced it expects record revenue in the third quarter.
Company Presents Data Further Demonstrating Significant Benefits of ICELL8 Single-Cell System to Single-Cell Researchers
System Isolates More Than 10,000 Single Cells Per Day and Automatically Selects Cells to Process